Convergence Science Non-Clinical PhD
Data Science
Overview
The CRUK Convergence Science Centre (CSC) is partnering with the EPSRC for CDT in Statistics and Machine Learning (StatML) to provide a 4 year PhD studentship. This programme will train the future academic leaders in cancer research and statistical machine learning.
STUDENT APPLICATIONS ARE NOW OPEN. The deadline is Wednesday 8th January, 12pm midday (UK time). Please see our student information page for more details.
World class training
Students will follow the four-year version of the non-clinical PhD training programme. You will be trained by world leading experts in cancer biology, engineering and physical sciences at Imperial and the ICR. This will enable you to acquire a broad skill set and learn the language of multiple disciplines.
High-quality research outputs
With a range of outputs spanning research publications, presentations at relevant conferences, the PhD will provide you the grounding for your future success as a convergence scientist.
Convergence Science Centre Bespoke Training programme
The scientific landscape is constantly evolving, with disciplines merging into novel entities. To navigate interdisciplinary research, our students are required to develop flexibility by learning to integrate diverse skill sets. To support them, we've designed a training programme aimed at developing skills required to work across the boundaries of different disciplines.
The studentship will cover tuition fees at home rate and stipend (£23,000 per year) for a total of 4 years. In addition, there is a Research Training and Support Grant to cover travel, conference participation, academic placements and consumables as allowed under the terms and conditions of CRUK and EPSRC.
The standard Convergence Science Centre PhD programme and studentship academic eligibility criteria are:
A first or upper second-class honours degree (or equivalent from a non-UK university) in a relevant subject.
A master’s degree in a relevant subject
Appropriate English language skills.
More information coming soon.
